SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 38.07 |
Enterprise Value ($M) | 26.94 |
Book Value ($M) | 156.43 |
Book Value / Share | 3.71 |
Price / Book | 0.24 |
NCAV ($M) | 115.60 |
NCAV / Share | 2.74 |
Price / NCAV | 0.33 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.75 |
Return on Assets (ROA) | -0.47 |
Return on Equity (ROE) | -0.55 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 7.04 |
Current Ratio | 7.04 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 156.39 |
Assets | 197.22 |
Liabilities | 40.79 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Vaddi Krishna | |||
13G/A | Flynn James E | |||
13G/A | Ubs Asset Management Americas Inc | 0.00 | -100.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
63,942 | 153,464 | 41.67 | |
65,012 | 162,520 | 40.00 | |
61,229 | 162,381 | 37.71 | |
46,584 | 198,289 | 23.49 | |
(click for more detail) |
Similar Companies | |
---|---|
PLRX – Pliant Therapeutics, Inc. | PMVP – PMV Pharmaceuticals, Inc. |
PRAX – Praxis Precision Medicines, Inc. | PRTA – Prothena Corporation plc |
PTCT – PTC Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io